Supriya Lifescience Ltd., a cGMP-compliant company with a solid track record in API manufacturing and an emphasis on products from a range of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anesthetic, and anti-asthmatic, has released the unaudited financial statements for the Q2FY25 results. The corporation has expanded its operations to over 86 countries worldwide.
Key Consolidated Financial Highlights for Q2FY25:
| Particulars | Q2 FY25 | Q2 FY24 | Y-o-Y |
| Revenues (in Rs Cr) | Rs. 166.1 | Rs. 140.1 | 18.6% |
| Gross Profit (in Rs Cr) | Rs. 120.13 | Rs.78.46 | 53.1% |
| EBITDA (in Rs Cr) | Rs. 64.72 | Rs. 31.75 | 103.8% |
| EBITDA Margin | 39.0% | 22.7% | +1630 Bps |
| PAT (in RsCr) | Rs. 46.15 | Rs. 23.88 | 93.2% |
| PAT Margin | 27.8% | 17.0% | +1074 Bps |
| EPS (in Rs) | 5.71 | 2.97 |
Key Consolidated Financial Highlights for H1FY25:
| Particulars | H1 FY25 | H1 FY24 | Y-o-Y |
| Revenues (in Rs Cr) | Rs. 326.7 | Rs. 272.1 | 20.1% |
| Gross Profit (in Rs Cr) | Rs. 232.1 | Rs.163.2 | 42.2% |
| EBITDA (in Rs Cr) | Rs. 127.2 | Rs. 75.9 | 67.5% |
| EBITDA Margin | 38.9% | 27.9% | +1103 Bps |
| PAT (in RsCr) | Rs. 907.9 | Rs. 523.9 | 73.3% |
| PAT Margin | 27.8% | 19.3% | +853 Bps |
| EPS (in Rs) | 11.25 | 6.51 |
Key Highlights for Q2 FY25:
- Supriya Lifescience Ltd.’s revenue increased by 18.6% year over year to Rs. 166.1 crore in the second quarter of FY25 from Rs. 140.1 crore in the same period the previous year.
- In comparison to Q2 FY24’s gross profit of Rs. 78.46 crore, the gross profit for Q2 FY25 increased by 53.1% to Rs. 120.13 crore.
- Compared to Q2 FY24, when EBITDA was Rs. 31.75 crore with an EBITDA margin of 22.7%, Q2 FY25’s EBITDA was Rs. 64.72 crore with an EBITDA margin of 39.0%. This is a 103.8% YoY growth.
- In Q2 FY24, the Profit After Tax (PAT) was Rs 23.88 crore; in Q2 FY25, it was Rs 46.15 crore.
- In Q2 of FY25, the PAT Margin was 27.8%, while in Q2 of FY24, it was 17.0%.
- The business growth in Q2 was driven by the analgesic and anesthetic category, which contributed 54.9% of sales, up from 50.0% in Q2FY24. Compared to 7.2%, the anti-asthmatic category contributed 9.2%.
- In H1FY25, European markets accounted for 45% of our company’s revenue, up from 39% in H1FY24.
- Three ANDA projects for anesthetic therapy have been started, and the business is also working on ANDA projects for vitamins and antihypertensive medications.
- After a new capacity addition, capacity utilization jumped from 47% in FY22 to 86% in FY24. The corporation has purchased three distinct land parcels close to major operations in order to assist the future expansion of different business sectors.
- With more than 1,700 clients in more than 128 countries, Supriya Lifescience Ltd. is still growing its global presence. The business has carefully divided these geographical areas among its committed sales teams in order to guarantee steady growth and future expansion through the acquisition of new clients.
Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the results, said, “Our commitment to innovation through R&D is paving the way for sustained growth and expansion. With the commissioning of our advanced R&D lab at Lote Parshuram and the upcoming Ambernath facility, we’re focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio. Expanding our global presence across key regions, we’re also working closely with regulatory and sales teams to acquire new customers, particularly in regulated markets. Our recent exclusive 10-year contract with a leading European firm underscores our capabilities in handling complex chemical processes, setting the stage for similar opportunities. As we enhance our infrastructure, including increasing capacity at Lote Parshuram to 1,020 KL by Q3 FY25, we’re building a foundation for a stronger future.”
